🔗 Share this article

Given that America undertakes historic changes to its vaccination schedules, an unexpected name has emerged in a surprising turn: Høeg, a Danish American sports physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines during the global health crisis and has focused upon alleged deaths following COVID-19 immunization in her recent time at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Agency leaders had intended to announce sweeping revisions to the childhood vaccination calendar recently, aligning the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US at odds with a large portion of the international standard with no evidence for improved outcomes. The planned update has been postponed until the coming year.

Rather than Vinay Prasad, Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the center this year.

A New Direction at the Agency

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for ending certain childhood immunization guidelines in the US so as to align more similar to Denmark, a society with universal health coverage and a population approximately the population of the state of Wisconsin.

To date statements, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Expertise

Høeg has little discernible experience in medication creation, oversight or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She has no expertise in running a sizeable institution. She has no expertise in drug approvals.”

Previous directors of the center would “grasp laws and regulations and the science of medication creation”, said Janet Woodcock. “Objectively, she lacks the kind of background that previous people who headed CBER have had.”

The drug center has an vast portfolio at the agency, the former commissioner pointed out.

“The public just focuses on the innovative therapies, but the generic drug division approves a multitude of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and each of these need to be looked after,” she noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a major management element to the role, which manages more than 5,000 employees. “It’s a massive leadership role, if you do it right,” she concluded.

Response and Disputed Programs

In response to concerns about Dr. Høeg's qualifications and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “questions rely on inaccurate presumptions”.

“This background matches the functions of her job,” the official explained, citing the months Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's new fast-track approval initiative, a controversial rapid therapy clearance system that reportedly worried her former heads. “How are these medications being selected for this fast-track system? Who is making the choices?” Dr. Howard said. “There’s a lot of confidentiality happening at the regulatory body right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed rules of most medications, aside from immunizations.”

Public History on Vaccines

With vaccines, Høeg has a clearer, if troubling, history, Howard have noted. She released a study using unverified public submissions to estimate the frequency of heart inflammation following COVID-19 vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are pose a greater threat than they are.

Among her “desired changes” for the new government encompassed revising regulations for recently developed shots and ending “non-essential” immunizations, she remarked following the vote on a online show. At the FDA, Dr. Høeg has according to sources proposed preventing adolescent males from receiving Covid vaccines.

“She is an thorough true believer who begins with her beliefs and tailors the evidence to fit the evidence in a very deceptive, fraudulent fashion,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow dissenters, {like|